Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Innate Pharma (IPHA) Net Income - Minority (2018 - 2024)

Historic Net Income - Minority for Innate Pharma (IPHA) over the last 7 years, with Q4 2024 value amounting to -$9.4 million.

  • Innate Pharma's Net Income - Minority rose 8309.53% to -$9.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$9.4 million, marking a year-over-year increase of 8309.53%. This contributed to the annual value of -$9.4 million for FY2024, which is 8309.53% up from last year.
  • Per Innate Pharma's latest filing, its Net Income - Minority stood at -$9.4 million for Q4 2024, which was up 8309.53% from -$55.8 million recorded in Q4 2023.
  • Innate Pharma's Net Income - Minority's 5-year high stood at -$9.4 million during Q4 2024, with a 5-year trough of -$228.8 million in Q2 2020.
  • In the last 5 years, Innate Pharma's Net Income - Minority had a median value of -$89.4 million in 2021 and averaged -$109.7 million.
  • Its Net Income - Minority has fluctuated over the past 5 years, first crashed by 107.69% in 2023, then soared by 8309.53% in 2024.
  • Innate Pharma's Net Income - Minority (Quarter) stood at -$186.0 million in 2020, then surged by 33.91% to -$122.9 million in 2021, then surged by 55.05% to -$55.2 million in 2022, then fell by 1.08% to -$55.8 million in 2023, then surged by 83.1% to -$9.4 million in 2024.
  • Its Net Income - Minority was -$9.4 million in Q4 2024, compared to -$55.8 million in Q4 2023 and -$55.2 million in Q4 2022.